Media Articles Related to Nicotrol NS (Nicotine Nasal)
PodMed: A Medical News Roundup From Johns Hopkins (with audio)
Source: MedPageToday.com - medical news plus CME for physicians [2014.08.23]
(MedPage Today) -- This week?s topics include a new drug for multidrug-resistant tuberculosis, concussion in adolescent girls, cancer screening in the elderly, and smoking cessation after hospital discharge.
Intervention helps smokers quit following hospital stay
Source: Smoking / Quit Smoking News From Medical News Today [2014.08.19]
Among hospitalized adult smokers who wanted to quit, a postdischarge intervention that included automated telephone calls and free medication resulted in higher sustained smoking cessation rates at...
Incentives to breastfeed and quit smoking backed by the young
Source: Smoking / Quit Smoking News From Medical News Today [2014.07.18]
Men and women aged 44 or younger are more likely to agree with financial incentives to encourage breast feeding and smoking cessation during pregnancy compared to those aged 65 and over.
Published Studies Related to Nicotrol NS (Nicotine Nasal)
Nicotine nasal spray as an adjuvant analgesic for third molar surgery. [2011.05]
PURPOSE: To determine the efficacy of preoperatively administered nicotine nasal spray (3 mg) for analgesia after third molar (TM) surgery... CONCLUSION: Pain is well controlled by hydrocodone/acetaminophen in most patients after TM surgery. However, there is significant variability in pain reported. Nicotinic agonists represent a new class of analgesic that can be considered for patients who are expected to have significant opioid-resistant pain after TM surgery. Caution should be used with patients in whom a small increase in heart rate would be deleterious. Copyright (c) 2011 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.
Direction and magnitude of nicotine effects on the fMRI BOLD response are related to nicotine effects on behavioral performance. [2011.05]
Considerable variability across individuals has been reported in both the behavioral and fMRI blood oxygen level-dependent (BOLD) response to nicotine. We aimed to investigate (1) whether there is a heterogeneous effect of nicotine on behavioral and BOLD responses across participants and (2) if heterogeneous BOLD responses are associated with behavioral performance measures...
Treating heavy smokers in primary care with the nicotine nasal spray: randomized placebo-controlled trial. [2011.04]
AIMS: Of six established nicotine replacement therapy (NRT) formulations, only the gum and patch have been tested without specialist clinic support in placebo-controlled trials. We aimed to broaden the evidence base by examining if the nicotine nasal spray (NNS) could be effective with only brief support in general practice... CONCLUSIONS: NNS is effective when given in primary care. The benefit was lower than in a specialist clinic but similar to that with the nicotine patch in primary care. Unlike most other NRT formulations, bupropion or varenicline, NNS was especially helpful for more dependent smokers. Continuing treatment of those initially failing was not beneficial. An initial 1-week prescription to those more dependent on nicotine is likely to be the most cost-effective NNS treatment protocol. These results should offer support to the effectiveness of the other NRT formulations untested in this setting. (c) 2011 The Authors, Addiction (c) 2011 Society for the Study of Addiction.
Treating heavy smokers in primary care with the nicotine nasal spray: randomized
placebo-controlled trial. 
general practice... CONCLUSIONS: NNS is effective when given in primary care. The benefit was lower
Effects of nicotine patch or nasal spray on nicotine and cotinine concentrations in pregnant smokers. [2009.09]
OBJECTIVE: To examine the short-term effects of the nicotine patch or nasal spray on measures of nicotine exposure, withdrawal symptoms, and on maternal and fetal heart rates in pregnant smokers... CONCLUSIONS: Nicotine patch and nasal spray reduce maternal nicotine exposure compared with smoking and may be effective for smoking cessation.
Clinical Trials Related to Nicotrol NS (Nicotine Nasal)
Adjustment of DOses of NIcotine in Smoking Cessation (ADONIS) [Completed]
Nicotine replacement therapies (NRT) have proven efficacy to help smokers quit. However,
their effectiveness is low. This study aims to answer the question: Does the dose adjustment
of NRT according the saliva concentration of nicotine's main metabolite: cotinine improve
their efficacy compared with the lack of dose adjustment (usual care) in smoking patients
with smoking related disease condition.
A Pilot Drug Trial That Evaluates the Whitening Potential of Nicotine Gum [Completed]
The purpose of this research study is to evaluate the effects on existing tooth stain of
nicotine gum. The study will enroll adults who have visible tooth staining.
Assessment of High Dose Transdermal Nicotine for Fast Metabolizers of Nicotine [Recruiting]
Unfortunately, the investigators still need to assess and identify novel ways to help people
quit smoking. Differences between people in terms of how fast they metabolize nicotine
influences response to transdermal nicotine patches, the most popular nicotine dependence
treatment, and it affects plasma levels of nicotine from treatment. These studies suggest
that fast metabolizers of nicotine may show better quit rates if they receive higher doses
of transdermal nicotine. This preliminary study is designed to assess, for the first time,
whether fast nicotine metabolizers show higher quit rates if given high dose transdermal
nicotine, versus standard dose. The study findings may help to support a subsequent large
trial to assess standard versus high dose transdermal nicotine for slow versus fast
metabolizers of nicotine, which may lead to a more personalized approach to treating
nicotine dependence using the nicotine patch to improve therapeutic benefits of transdermal
Nicotine Vaccination and Nicotinic Receptor Occupancy [Recruiting]
This is a molecular imaging research study designed to examine how much nicotine gets into
the brain before and after vaccination with NicVAX, a nicotine vaccine developed by Nabi
Biopharmaceuticals. NicVAX (Nicotine Conjugate Vaccine) is an investigational vaccine
designed as an aid to smoking cessation and long-term abstinence, as well as an aid to
prevent relapses of a treated smoker.
In this project we want to understand the degree to which NicVAX administration changes how
much nicotine enters the brain in smokers.
Bio-Behavioral Predictors of the Efficacy of Nicotine Replacement Therapy (NRT) [Active, not recruiting]
The purpose of this research study is to:
1. compare the effectiveness of a nicotine patch and nicotine nasal spray for smoking
2. identify predictors of response to these alternate forms of nicotine replacement therapy
The ultimate objective is to obtain information necessary to match NRT to those smokers with
the greatest need and likelihood of benefit. The investigators hypothesize that the nicotine
nasal spray (NS) will result in significantly higher abstinence rates than transdermal
nicotine (TN) for the following subgroups of smokers: those with genotypes associated with
less transmission of dopamine or serotonin, or greater metabolism of nicotine; and those with
higher levels of novelty-seeking, depression, and attention deficit symptoms.